Drug Buyers Urge Class Cert. In Cephalon Off-Label Use Suit

Law360, Philadelphia (July 24, 2013, 4:38 PM EDT) -- Two entities that pay for employees' prescription drugs on Wednesday asked a Pennsylvania federal judge to certify a class of other purchasers in a suit alleging that drug manufacturer Cephalon Inc. illegally pushed off-label uses for its painkiller Actiq.

Attorney Steve Berman of Hagens Berman Sobol Shapiro LLP told U.S. District Court Chief Judge Petrese Tucker that, according to a recent First Circuit ruling, a demonstration that Pennsylvania-based Cephalon had engaged in an off-label marketing scheme for the drug was sufficient to certify the class....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.